New insights into how certain slow progressers control HIV infection

September 19, 2012

People with a rare genetic trait who are infected with HIV progress more slowly to AIDS than others. But even within this group, there are wide variations in time to progression. A new study illustrates in detail how the immune system fights the virus in those subjects who progress more slowly. The research, which could prove useful to efforts to develop a vaccine against HIV, is published in the September Journal of Virology.

Absent , most of those infected with HIV progress to AIDS within a decade. But 5-15 percent remain symptom free for years even without therapy. A portion of these people maintain high CD4+T immune cell counts, along with low levels of virus for several years. Many of these people possess the afore-mentioned rare , the awkwardly-named HLA-B*5701 allele (an allele is one possible version of a gene), and their time of progression can range from around six years to well beyond ten years.

The researchers, led by Melissa M. Norstrom and Annika K. Karlsson of the Karolinska Institute, Stockholm, Sweden, and Marco Salemi of the University of Florida, Gainesville, studied evolution of HIV, and immune responses in six untreated HIV-infected patients carrying the protective genetic trait, following them from soon after infection, for seven years. In particular, they studied a set of molecules that are produced by called CD8+T cells, which are involved in combating .

"We found that subjects with lower risk of progressing to AIDS were characterized by a higher proportion of CD8+T cells that produced several of these molecules simultaneously," says Norstrom. They also found that in these patients, the virus evolved much more slowly. Further, viral mutations, which normally occur somewhat haphazardly during , appeared to happen in a specific order, which the researchers postulate resulted from selective constraints exerted by the immune system.

"Understanding the mechanisms associated with slower progression to AIDS may ultimately provide new insights on how to cure HIV, or even how to develop a protective vaccine," says Salemi.

The research had a serendipitous origin, when Norstrom and Salemi met at a workshop on viral evolution, says Salemi. "The exciting discussions during that scientific meeting led to establishment of a successful multidisciplinary collaboration, which included experts in immunology and viral evolution, as well as with Dr. [Frederick M.] Hecht at the University of California, San Francisco, who provided samples from patients carrying this unique genetic trait."

Explore further: Study finds HIV-specific CD4 cells that control viral levels

More information: M.M. Norstrom, M. Buggert, J. Tauriainen, W. Hartogensis, M.C. Prosperi, M.A. Wallet, F.M. Hecht, M. Salemi, and A.C. Karlsson, 2012. Combination of immune and viral factors distinguishes low-risk versus high-risk HIV-1 disease progression in HLA-B*5701 Subjects. J. Virol. 86:9802-9816.

Related Stories

Study finds HIV-specific CD4 cells that control viral levels

February 29, 2012

A subpopulation of the immune cells targeted by HIV may play an important role in controlling viral loads after initial infection, potentially helping to determine how quickly infection will progress. In the February 29 issue ...

HIV-2 infection inhibits HIV-1 disease progression

July 19, 2012

(HealthDay) -- While many people don't know it, there's more than one kind of AIDS virus. Besides the HIV-1 strain that's common throughout the world, a type known as HIV-2 is found in some parts of Africa. Now, a new study ...

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.